Shots:

• The approval is based in the clinical program including P-I & II trials- and three P-III trials evaluating the safety & immunogenicity of Prevnar 20 in adults aged ≥18yrs. with invasive disease and pneumonia caused by the 20 S. pneumoniae serotypes
• This is the first approval of a vaccine that protects against 20 serotypes responsible for most of the invasive pneumococcal disease and pneumonia-1-2-3-4-5-6-7 including seven responsible for 40% of pneumococcal disease cases and deaths in the US
• The therapy has previously received BTD and FTD from FDA for the prevention of invasive disease and pneumonia in adults age 18 years or older and PREVNAR 20 is currently under EMA’s review

  | Ref: Business Wire | Image: The Wall Street Journal